{"filing":{"accession_number":"0001193125-26-387197","cik":"0001314102","ticker":"EYPT","company_name":"EyePoint, Inc.","form":"8-K","filing_date":"2026-09-10","report_date":"2026-09-10","primary_document":"eypt-20260910.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-20260910.htm"},"events":[{"id":32507,"run_id":29871,"accession_number":"0001193125-26-387197","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"EyePoint disclosed updated clinical trial results and analyses for its Phase 3 LUGANO wet AMD trial for DURAVYU, posted to its investor website and filed as Exhibit 99.1. While the trial did not achieve its primary endpoint of statistical non-inferiority in the full dataset, the presentation details expanded analyses showing non-inferiority when excluding an asymmetric cohort, strong anatomic control, and superior treatment burden reduction. This represents a material operational/clinical development milestone affecting investor expectations for the planned 1H 2027 NDA filing, though the mixed primary endpoint result creates genuine uncertainty about regulatory pathway success.","company_name":"EyePoint, Inc.","ticker":"EYPT","filing_date":"2026-09-10","form":"8-K","submitted_at":null,"items":[{"id":35696,"accession_number":"0001193125-26-387197","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"EyePoint disclosed updated clinical trial results and analyses for its Phase 3 LUGANO wet AMD trial for DURAVYU, posted to its investor website and filed as Exhibit 99.1. While the trial did not achieve its primary endpoint of statistical non-inferiority in the full dataset, the presentation details expanded analyses showing non-inferiority when excluding an asymmetric cohort, strong anatomic control, and superior treatment burden reduction. This represents a material operational/clinical development milestone affecting investor expectations for the planned 1H 2027 NDA filing, though the mixed primary endpoint result creates genuine uncertainty about regulatory pathway success.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T11:06:41.423346+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35696,"accession_number":"0001193125-26-387197","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"EyePoint disclosed updated clinical trial results and analyses for its Phase 3 LUGANO wet AMD trial for DURAVYU, posted to its investor website and filed as Exhibit 99.1. While the trial did not achieve its primary endpoint of statistical non-inferiority in the full dataset, the presentation details expanded analyses showing non-inferiority when excluding an asymmetric cohort, strong anatomic control, and superior treatment burden reduction. This represents a material operational/clinical development milestone affecting investor expectations for the planned 1H 2027 NDA filing, though the mixed primary endpoint result creates genuine uncertainty about regulatory pathway success.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T11:06:41.423346+00:00","company_name":"EyePoint, Inc.","ticker":"EYPT","filing_date":"2026-09-10"}]}